Navigation Links
Medco Announces Two-For-One Stock Split

FRANKLIN LAKES, N.J., Nov. 29 /PRNewswire-FirstCall/ -- Medco Health Solutions, Inc. (NYSE: MHS) today announced that its Board of Directors has approved a two-for-one stock split. The stock split, effected in the form of a dividend, will entitle all shareholders of record at the close of business on Jan. 10, 2008 to receive one additional share of Medco common stock for each share held on that date. The stock dividend will be distributed on Jan. 24, 2008.

Since becoming a public company in August 2003, Medco's stock has appreciated approximately four-fold.

"By concentrating our resources on breakthrough innovations that deliver clinical and financial value to our clients and members, we have, in turn, delivered a consistent track record of building wealth for our shareholders," said David B. Snow Jr., Medco chairman and CEO. "Following this strategy that leverages key growth drivers -- including generics, mail order, specialty pharmacy, and Medicare, and our success in driving net-new business -- we are confident that we will continue to grow shareholder value."

About Medco

Medco Health Solutions, Inc. (NYSE: MHS) is the nation's leading pharmacy benefit manager based on its 2006 total net revenues of more than $42 billion. Medco's prescription drug benefit programs, covering one in five Americans, are designed to drive down the cost of pharmacy health care for private and public employers, health plans, labor unions and government agencies of all sizes, and for individuals served by the Medicare Part D Prescription Drug Program. Medco, the world's most advanced pharmacy(TM) has created Therapeutic Resource Centers(TM) that are staffed with hundreds of specialist pharmacists trained and certified in specific chronic and complex conditions and have expertise in the medications that treat them. Medco is the nation's largest diabetes pharmacy care practice based on covered lives with the 2007 acquisition of the Liberty Medical, and the largest specialty pharmacy based on net revenues with the 2005 acquisition of Accredo Health, Incorporated. Medco is the highest-ranked independent pharmacy benefit manager on the 2007 Fortune 500 list. On the Net:

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward- looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about the business and future financial results of the pharmacy benefit management ("PBM") and specialty pharmacy industries, and other legal, regulatory and economic developments. We use words such as "anticipates," "believes," "plans," "expects," "projects," "future," "intends," "may," "will," "should," "could," "estimates," "predicts," "potential," "continue," "guidance" and similar expressions to identify these forward-looking statements. Medco's actual results could differ materially from the results contemplated by these forward-looking statements due to a number of factors. These factors include:

-- Competition in the PBM, specialty pharmacy and the broader health care

industry is intense and could impair our ability to attract and retain


-- Failure to retain key clients could result in significantly decreased

revenues and could harm our profitability;

-- If we do not continue to earn and retain purchase discounts and rebates

from manufacturers at current levels, our gross margins may decline;

-- Our acquisition activity increased recently and if we are unable to

effectively integrate acquired businesses into ours, our operating

results may be adversely affected;

-- If we fail to comply with complex and rapidly evolving laws and

regulations, we could suffer penalties, or be required to pay

substantial damages or make significant changes to our operations;

-- Government efforts to reduce health care costs and alter health care

financing practices could lead to a decreased demand for our services

or to reduced profitability;

-- Failure to execute our Medicare Part D prescription drug benefits

strategy could adversely impact our business and financial results;

-- PBMs could be subject to claims under ERISA if they are found to be a

fiduciary of a health benefit plan governed by ERISA;

-- Pending litigation could adversely impact our business practices and

have a material adverse effect on our business, financial condition,

liquidity and operating results;

-- We are subject to corporate integrity agreements and noncompliance may

impede our ability to conduct business with the federal government;

-- Legislative or regulatory initiatives that restrict or prohibit the PBM

industry's ability to use patient identifiable medical information

could limit our ability to use information that is critical to the

operation of our business;

-- Our specialty pharmacy business is dependent on our relationships with

a limited number of biopharmaceutical suppliers and the loss of any of

these relationships could significantly impact our ability to sustain

or increase our revenues;

-- Our ability to grow our specialty pharmacy business could be limited if

we do not expand our existing base of drugs or if we lose patients;

-- Our specialty pharmacy business and Medicare Part D offerings expose us

to increased credit risk;

-- Changes in industry pricing benchmarks could adversely affect our

financial performance;

-- The terms and covenants relating to our existing indebtedness could

adversely impact our financial performance;

-- Prescription volumes may decline, and our net revenues and

profitability may be negatively impacted, if products are withdrawn

from the market or if increased safety risk profiles of specific drugs

result in utilization decreases;

-- We may be subject to liability claims for damages and other expenses

that are not covered by insurance;

-- The success of our business depends on maintaining a well-secured

pharmacy operation and technology infrastructure and failure to execute

could adversely impact our business;

-- We could be required to record a material non-cash charge to income if

our recorded intangible assets are impaired, or if we shorten

intangible asset useful lives; and,

-- Anti-takeover provisions of the Delaware General Corporation Law

("DGCL"), our certificate of incorporation and our bylaws could delay

or deter a change in control and make it more difficult to remove

incumbent officers and directors.

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other uncertainties and potential events described in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other documents filed from time to time with the Securities and Exchange Commission.

SOURCE Medco Health Solutions, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. MedCom USAs Subsidiary Card Activation Technologies, Inc.s SB2 Registration Declared Effective by SEC
2. Medco Unveils Three New Medicare Prescription Drug Plan Options for 2008 to Provide Seniors More Choice, Better Value and Specialist Pharmacists
3. Medco Announces Date for Third-Quarter 2007 Financial Results
4. Six Olympic Legends Battling Chronic Diseases Lead Revolution in Advancing Pharmacy Care as Medco Launches the Tour of Champions
5. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
6. Medco to Build Worlds Largest, Most Advanced Automated Pharmacy in Central Indiana
7. Medco Elects Myrtle Potter, William Roper to Board of Directors
8. Medco CEO to Present at the Merrill Lynch & Co., Inc. 2007 Health Services Investor Conference
9. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
10. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
11. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
Post Your Comments:
(Date:11/26/2015)... ON (PRWEB) , ... November 26, 2015 , ... ... of a real-time eReferral system for diagnostic imaging in the Waterloo region. Using ... BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) without ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, Inc., ... the 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted by ... through Wednesday, November 11th, 2015. The conference was held at the Hawaii Convention ...
(Date:11/25/2015)... ... 25, 2015 , ... As part of a global movement ... volunteers together who want to combine talents and resources to help create sustainable ... process. The non-profit launched its first major fundraiser on November 6, 2015 at ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical ... more about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared ... thicker and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
(Date:11/25/2015)... ... 25, 2015 , ... Lakeview Health, a Jacksonville-based drug and ... sobriety and show through pictures what a positive difference it makes. The social ... the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. Short stories ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... -- The American Academy of Pediatrics (AAP), American Congress ... of Dimes cheered today,s signature into law of ... 2015 (S.799), which takes much-needed strides to ... drugs, such as opioids, and to improve their ... have worked together leading advocacy efforts for its ...
(Date:11/25/2015)... Nov. 25, 2015  Henry Schein, Inc., the world,s ... office-based dental, medical and animal health practitioners, will unveil ... Henry Schein ConnectDental® Pavilion , which brings together ... open solutions designed to help any practice or laboratory ... for a schedule of experts appearing at the ...
(Date:11/25/2015)... 25, 2015 Allergan plc (NYSE: ... Rugen Therapeutics, a start-up  biotechnology company focused on ... disorders and funded by the F-Prime Biomedical Research ... into an exclusive collaboration to support the discovery ... Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
Breaking Medicine Technology: